Inflammatory Bowel Disease: Crosstalk between Histamine, Immunity, and Disease DOI Open Access
Kristina A. Dvornikova, Olga N. Platonova, E. Yu. Bystrova

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(12), P. 9937 - 9937

Published: June 9, 2023

Inflammatory bowel disease (IBD) is increasingly recognized as a serious, worldwide public health concern. It generally acknowledged that variety of factors play role in the pathogenesis this group chronic inflammatory diseases. The diversity molecular actors involved IBD does not allow us to fully assess causal relationships existing such interactions. Given high immunomodulatory activity histamine and complex immune-mediated nature disease, its receptors gut may be significant. This paper has been prepared provide schematic most important possible signaling pathways related their relevance for development therapeutic approaches.

Language: Английский

Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis DOI Creative Commons
Xu-Dong Tang, Yangyang Shang, Hong Yang

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Feb. 23, 2024

The PD-1/PD-L1 pathway in mucosal immunity is currently actively explored and considered as a target for inflammatory bowel disease (IBD) treatment. However, systemic PD-L1 administration may cause unpredictable adverse effects due to immunosuppression. Here we show that reactive oxygen species (ROS)-responsive nanoparticles enhance the efficacy safety of mouse colitis model. control accumulation release fused Fc (PD-L1-Fc) at sites colon. nanotherapeutics shows superiority alleviating symptoms over PD-L1-Fc mitigates administration. nanoparticles-formulated affects production proinflammatory anti-inflammatory cytokines, attenuates infiltration macrophages, neutrophils, dendritic cells, increases frequencies Treg, Th1 Tfh reshapes gut microbiota composition; short-chain fatty acid production. In summary, PD-L1-Fc-decorated provide an effective safe strategy targeted treatment IBD.

Language: Английский

Citations

9
Recent advances in intestinal fibrosis DOI
Marco Vincenzo Lenti, Giovanni Santacroce, Giacomo Broglio

et al.

Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: 96, P. 101251 - 101251

Published: Feb. 14, 2024

Language: Английский

Citations

8
Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date DOI Open Access
Alessandro Giammona, Bruno G. Galuzzi, Elena Imperia

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(1), P. 413 - 413

Published: Jan. 6, 2025

Chronic gastrointestinal disorders such as inflammatory bowel diseases (IBDs) and irritable syndrome (IBS) impose significant health burdens globally. IBDs, encompassing Crohn’s disease ulcerative colitis, are multifactorial characterized by chronic inflammation of the tract. On other hand, IBS is one principal tract functional abdominal pain altered habits. Although precise etiopathogenesis these remains unclear, mounting evidence suggests that non-coding RNA molecules play crucial roles in regulating gene expression associated with inflammation, apoptosis, oxidative stress, tissue permeability, thus influencing progression. miRNAs have emerged possible reliable biomarkers, they can be analyzed biological fluids patients at a low cost. This review explores IBDs IBS, focusing on their involvement control hallmarks. By an extensive literature employing bioinformatics tools, we identified frequently studied concerning diseases. Ultimately, specific could proposed diagnostic biomarkers for IBS. Their ability to secreted into biofluids makes them promising candidates non-invasive tools. Therefore, understanding molecular mechanisms through ways which regulate immune responses provide new insights pathogenesis open avenues miRNA-based therapeutic interventions.

Language: Английский

Citations

1
Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern Europeans DOI Creative Commons
Ben Krause‐Kyora, Nicolas Antonio da Silva, Elif Kaplan

et al.

EBioMedicine, Journal Year: 2025, Volume and Issue: 113, P. 105591 - 105591

Published: Feb. 8, 2025

Language: Английский

Citations

1
Inflammatory bowel disease in south Asia: a scoping review DOI
Smita Shenoy, Anuraag Jena, Carrie Levinson

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2025, Volume and Issue: 10(3), P. 259 - 274

Published: Feb. 12, 2025

Language: Английский

Citations

1
Accelerated biological aging and risk of inflammatory bowel disease: A prospective study from 401,013 participants DOI Creative Commons

Baolong Cao,

Xiaoke Zhao,

Zhixi Lu

et al.

The journal of nutrition health & aging, Journal Year: 2025, Volume and Issue: 29(4), P. 100505 - 100505

Published: Feb. 13, 2025

Language: Английский

Citations

1
PPARγ/β/δ Agonists Can Ameliorate Dextran Sodium Sulfate–Induced Colitis and Modulate Gut Microbiota DOI Open Access
Jianhong Li, Jing Xu,

Jinxia Hu

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

ABSTRACT Background and Aim Peroxisome proliferator–activated receptors (PPARs), as nuclear receptors, modulate both lipid metabolism inflammatory/immune processes. This study examines the impact of modulating activities PPAR subtypes PPARβ/ð PPARγ on gut microbiota in inflammatory bowel disease (IBD). Methods Mice with dextran sulfate sodium (DSS)–induced acute colitis were treated agonist pioglitazone, PPARβ/δ GW0742, or their respective antagonists (GW9662, GSK3787). Weight loss, diarrhea severity, hematochezia, activity index assessed daily. Upon completion, colon length, histopathology, mRNA levels intestinal barrier markers measured. Occludin E‐cadherin via immunofluorescence analysis, cecal samples underwent 16S rRNA sequencing for analysis. Results Our findings revealed that agonists pioglitazone GW0742 effectively suppressed DSS‐induced colitis, improved clinical symptoms, reversed shortening, mitigated histological damage. Conversely, antagonists, GW9662 GSK3787, failed to alleviate inflammation sometimes exacerbated indicators. Both modulated dysbiosis by reducing abundance proinflammatory cytokine–associated microbiota, including Bacteroides , Enterococcus Escherichia‐Shigella while enhancing α‐diversity β‐diversity microbiome, restore equilibrium. Conclusion reveal activation can balance mice ameliorate experimental mice. Thus, have protective effects against IBD could serve novel therapeutic targets its treatment.

Language: Английский

Citations

1
Heat-Killed Bifidobacterium bifidum B1628 May Alleviate Dextran Sulfate Sodium-Induced Colitis in Mice, and the Anti-Inflammatory Effect Is Associated with Gut Microbiota Modulation DOI Open Access
Cuijiao Feng,

Weiqin Zhang,

Tao Zhang

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(24), P. 5233 - 5233

Published: Dec. 8, 2022

Inflammatory bowel disease (IBD) is a chronic inflammatory associated with gut dysbiosis. This study aimed to investigate the effects of heat-killed Bifidobacterium bifidum B1628 (HB1628) in dextran sulfate sodium (DSS)-induced colitis mice. The following three mouse groups were included (n = eight per group): NC (normal control), DSS (colitis), and HB1628 (colitis postbiotic). mice group showed significant weight loss histological damage, developed bloody diarrhea, scored high activity index (DAI), exhibited increases pro-inflammatory cytokines (interleukin [IL]-1β, IL-6, tumor necrosis factor [TNF]-α) decreases an anti-inflammatory cytokine (IL-13) serum. These changes accompanied by microbiota modulation (decreases Rikenellaceae Eubacterium; Peptostreptococcaceae, Bacteroides vulgatus, Parasutterella excrementihominis). had lower DAIs, histology scores, serum levels (IL-1β TNF-α), but higher (IL-13), compared group, suggesting less severe state after intervention. Additionally, improved DSS-induced dysbiosis, which evidenced intestinal beneficial bacteria, such as Lactobacillus, known unfavorable taxa IBD, e.g., Porphyromonadaceae, Subdoligranulum, Lachnospiraceae bacterium 3_1_46FAA, Alistipes indistinctus. Functional metagenomics revealed significantly enriched metabolic pathways (namely, aerobic respiration I [cytochrome c] pathway superpathways L-phenylalanine biosynthesis L-tryptophan biosynthesis, respectively). In conclusion, our results that effectively inflammation tissue damage mice, symptom relief effect was obvious remodulation.

Language: Английский

Citations

33
Pivotal Role of Inflammation in Celiac Disease DOI Open Access
Maria Vittoria Barone, Renata Auricchio, Merlin Nanayakkara

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(13), P. 7177 - 7177

Published: June 28, 2022

Celiac disease (CD) is an immune-mediated enteropathy triggered in genetically susceptible individuals by gluten-containing cereals. A central role the pathogenesis of CD played HLA-restricted gliadin-specific intestinal T cell response generated a pro-inflammatory environment. The mechanisms that generate this environment now starting to be addressed. In vitro study on cells and organoids, shows constant low-grade inflammation present also absence gluten. vivo studies population at risk, show before onset introduction gluten diet, cellular metabolic alterations cell-mediated response. Gluten exacerbates these constitutive vivo. Inflammation, may have main CD, adding tout court big family chronic inflammatory diseases. Nutrients can or anti-inflammatory effects, mediated microbiota. intestine function as crossroad for control both locally distance. aim review discuss recent literature natural history supported fragility with increased sensitivity other agents.

Language: Английский

Citations

31
Applications of human organoids in the personalized treatment for digestive diseases DOI Creative Commons
Qinying Wang,

Fanying Guo,

Yutao Jin

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Sept. 27, 2022

Abstract Digestive system diseases arise primarily through the interplay of genetic and environmental influences; there is an urgent need in elucidating pathogenic mechanisms these deploy personalized treatments. Traditional long-established model systems rarely reproduce either tissue complexity or human physiology faithfully; shortcomings underscore for better models. Organoids represent a promising research model, helping us gain more profound understanding digestive organs; this can also be used to provide patients with precise individualized treatment build rapid vitro test models drug screening gene/cell therapy, linking basic clinical treatment. Over past few decades, use organoids has led advanced composition each organ facilitated disease modeling, chemotherapy dose prediction, CRISPR-Cas9 intervention, high-throughput screening, identification SARS-CoV-2 targets, infection. However, existing mainly include epithelial system. In order reveal mechanism diseases, it necessary establish completer physiological organoid model. Combining techniques treatments different formulations approach that requires further exploration. This review highlights advancements field technology from perspectives modeling therapy.

Language: Английский

Citations

30